Biocept Inc (BIOC) - Product Pipeline Analysis, 2017 Update

Summary

Biocept Inc (Biocept) is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers related instrumentation, OncoCEE technology, and analytical capabilities for rare event detection and genetic characterization. The companys OncoCEE platform modifies rare cell capture and analyses methods. It offers patented methodology to isolate rare cells including circulating tumor cells, and cell-free circulating tumor DNA from the blood. The company also develops methodology to isolate cancer material including circulating tumor cells, and cell-free circulating tumor DNA. It serves medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Biocept is headquartered in San Diego, California, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Biocept Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Biocept Inc Company Overview 5
Biocept Inc Company Snapshot 5
Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Biocept Inc Pipeline Analysis Overview 8
Biocept Inc - Key Facts 8
Biocept Inc - Major Products and Services 9
Biocept Inc Pipeline Products by Development Stage 10
Biocept Inc Ongoing Clinical Trials by Trial Status 12
Biocept Inc Pipeline Products Overview 14
Companion Diagnostic Target Selector Test - SCLC 14
Companion Diagnostic Target Selector Test - SCLC Product Overview 14
MicroRNA Test - Lung Cancer 15
MicroRNA Test - Lung Cancer Product Overview 15
OncoCEE - CR (FISH) 16
OncoCEE - CR (FISH) Product Overview 16
preCEED 17
preCEED Product Overview 17
Target Selector CTC Test - EGFR Amplification 18
Target Selector CTC Test - EGFR Amplification Product Overview 18
Target Selector CTC Test - ESR1 19
Target Selector CTC Test - ESR1 Product Overview 19
Target Selector CTC Test - ESR1 Clinical Trial 20
Target Selector CTC Test - PR 21
Target Selector CTC Test - PR Product Overview 21
Target Selector CTC Test - PTEN Deletion 22
Target Selector CTC Test - PTEN Deletion Product Overview 22
Target Selector ctDNA Test - ALK 23
Target Selector ctDNA Test - ALK Product Overview 23
Target Selector ctDNA Test - ALK Clinical Trial 24
Target Selector ctDNA Test - ESR1 25
Target Selector ctDNA Test - ESR1 Product Overview 25
Target Selector ctDNA Test - NRAS 26
Target Selector ctDNA Test - NRAS Product Overview 26
Biocept Inc - Key Competitors 27
Biocept Inc - Key Employees 28
Biocept Inc - Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Biocept Inc, Recent Developments 30
May 11, 2017: Biocept Reports First Quarter 2017 Financial Results 30
Feb 15, 2017: Biocept Appoints Michael Terry Senior Vice President Commercial Operations 31
Jan 10, 2017: Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas 32
Dec 27, 2016: Columbia University Medical Center Sponsors Clinical Study Using Biocepts Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers 32
Dec 08, 2016: Clinical Utility of Biocepts Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium 33
Dec 07, 2016: Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biopsy Test at the 17th IASLC World Conference on Lung Cancer 33
Nov 09, 2016: Biocept Reports 2016 Third Quarter Financial Results 34
Oct 27, 2016: Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications 36
Oct 20, 2016: Study Results Presented at the 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance with Biocepts ctDNA Liquid Biopsy Platform vs. Tissue Biopsy 36
Sep 29, 2016: Clinical Results Demonstrating the Performance of Biocepts Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress 37
Appendix 38
Methodology 38
About GlobalData 40
Contact Us 40
Disclaimer 40

List Of Tables


Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Biocept Inc Pipeline Products by Equipment Type 6
Biocept Inc Pipeline Products by Indication 7
Biocept Inc Ongoing Clinical Trials by Trial Status 7
Biocept Inc, Key Facts 8
Biocept Inc, Major Products and Services 9
Biocept Inc Number of Pipeline Products by Development Stage 10
Biocept Inc Pipeline Products Summary by Development Stage 11
Biocept Inc Ongoing Clinical Trials by Trial Status 12
Biocept Inc Ongoing Clinical Trials Summary 13
Companion Diagnostic Target Selector Test - SCLC - Product Status 14
Companion Diagnostic Target Selector Test - SCLC - Product Description 14
MicroRNA Test - Lung Cancer - Product Status 15
MicroRNA Test - Lung Cancer - Product Description 15
OncoCEE - CR (FISH) - Product Status 16
OncoCEE - CR (FISH) - Product Description 16
preCEED - Product Status 17
preCEED - Product Description 17
Target Selector CTC Test - EGFR Amplification - Product Status 18
Target Selector CTC Test - EGFR Amplification - Product Description 18
Target Selector CTC Test - ESR1 - Product Status 19
Target Selector CTC Test - ESR1 - Product Description 19
Target Selector CTC Test - ESR1 - Biocepts Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers 20
Target Selector CTC Test - PR - Product Status 21
Target Selector CTC Test - PR - Product Description 21
Target Selector CTC Test - PTEN Deletion - Product Status 22
Target Selector CTC Test - PTEN Deletion - Product Description 22
Target Selector ctDNA Test - ALK - Product Status 23
Target Selector ctDNA Test - ALK - Product Description 23
Target Selector ctDNA Test - ALK - Evaluation of Liquid Biopsies in Localized and Advanced Lung Cancer Patients 24
Target Selector ctDNA Test - ESR1 - Product Status 25
Target Selector ctDNA Test - ESR1 - Product Description 25
Target Selector ctDNA Test - NRAS - Product Status 26
Target Selector ctDNA Test - NRAS - Product Description 26
Biocept Inc, Key Employees 28
Glossary 39

List Of Figures

List of Figures
Biocept Inc Pipeline Products by Equipment Type 6
Biocept Inc Pipeline Products by Development Stage 10
Biocept Inc Ongoing Clinical Trials by Trial Status 12

Biocept Inc (BIOC) - Product Pipeline Analysis, 2019 Update

Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers

USD 750 View Report

Biocept Inc (BIOC) - Financial and Strategic SWOT Analysis Review

Biocept Inc (BIOC) - Financial and Strategic SWOT Analysis Review

USD 300 View Report

Biocept Inc (BIOC) - Product Pipeline Analysis, 2019 Update

Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers

USD 750 View Report

Biocept Inc (BIOC) - Financial and Strategic SWOT Analysis Review

Biocept Inc (BIOC) - Financial and Strategic SWOT Analysis Review

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available